Global Digital Pathology Systems Industry

NEW YORK, Nov. 23, 2020 /PRNewswire/ --


Read the full report: https://www.reportlinker.com/p05205340/?utm_source=PRN



The global market for Digital Pathology Systems is expected to witness demand spike by 18.3% in the year 2020 highlighting a US$89.1million gains in annual revenue. Thereafter the market is expected to accelerate further and reach US$1.4 billion by the year 2027 trailing a CAGR of 13.9% over the analysis period 2020 to 2027.Pathology plays a huge role in the healthcare system and is a key part of clinical decision support. The pandemic has catalyzed the urgency of going digital and health systems are responding at lightning speeds. From telemedicine, wearable`s, IR monitoring to automation via use of robots, technology adoption is swift to ensure uninterrupted non-COVID care delivery with minimal infection risks. Deployment of IT is also gaining swift momentum as evidenced by rising demand for cloud solutions; analytics; sustainable supply chain solutions; EMR, EHR & digital pathology systems. With stay-at-home restrictions and the FDA`s decision to relax existing guidelines, various anatomic pathologists are embracing digital pathology to review images and slides from home. COVID-19 has resulted in dramatic decline in specimen referrals and associated revenues at anatomic pathology laboratories and groups. With the pandemic curtailing all but the most urgent cancer treatments and surgeries, histology laboratories are typically receiving extremely challenging tissue specimens for processing. In addition, there is a growing shortage of pathologists worldwide, with medical students entering the field failing to keep pace with the rate of retiring pathologists. Moreover, the strict physical distancing norms imposed to curb the spread of COVID-19 have led pathologists to stay of the lab.

However, amid the COVID-19 outbreak, new rules have been developed for allowing the increased usage of digital pathology and reading and reviewing of pathology slides and test results remotely, provided the test was initially performed in a CLIA-authorized laboratory. The pandemic prompted the CMS to ease restrictions for allowing pathologists to work and review pathology images remotely to reduce the risk of exposure to the virus. Applicable during the pandemic, the decision is bound to push capacity by supporting remote review of clinical results, laboratory data and pathology slides. The US FDA has temporarily eased guidelines pertaining to digital pathology services for encouraging medical professionals to remotely review scanned slides during COVID-19. The adoption of digital pathology is anticipated to reduce the exposure of pathologists to the virus and prevent disruption to critical pathology services. The new policy is applicable to Class-II digital pathology devices, and follows the CMS` decision to provide pathologists with the flexibility to remotely review clinical data, pathology studies and results during the outbreak. Prior to the COVID-19 pandemic, CMS guidelines under the Clinical Laboratory Improvement Amendments (CLIA) of 1988 prohibited clinicians from making primary diagnoses remotely. The regulation made it mandatory for pathologists to work in healthcare settings, hospitals or clinical laboratories holding the CLIA license. However, the pandemic prompted the CMS to suspend these requirements and allow pathologists to interpret and review cases remotely. The new policy from the FDA also allows the use of consumer monitors instead of medical-grade monitors. Pathologists can access images remotely over a secure VPN Internet connection to make diagnosis. In addition, the agency is making efforts to ensure access to remote digital pathology systems or devices amid the pandemic.

In short, although the world is in recession, it is not doomsday for digital health companies and VC funding will continue to increase given the unprecedented demand for digital health technology solutions. Future growth in the market will be driven by ever growing workload of pathologists; growing emphasis on quality of care and the resulting need for efficient, faster and cost-effective methods for accurate pathological assessment; and need for compliance with regulatory standards related to information management. Few of the benefits of digital pathology driving its adoption include digitalization of workflows; unification of patient data for more informed decision making; exposure to new clinical insights and data which adds to the volume of available expert knowledge; enables multi-disciplinary care by connecting multiple medical teams; enhanced workflow efficiency, reduced costs of operating pathological processes, quicker acquisition of high resolution images, and faster and accurate diagnosis. As healthcare moves to a value based system, zero tolerance to innate delays built into traditional pathology processes will drive growth of digital pathology systems. Focus on developing coherent and sustainable plans to address healthcare needs of the masses will drive increased investments in healthcare IT, especially in developing countries. Fully automated digital pathology are poised to witness strong growth in demand amid the rising emphasis on lab automation. Developments in laboratory information management system (LIMS) and network connectivity and speeds to enable digital pathology deliver on its promise of reduced diagnostic time in comparison with traditional microscopy will also be crucial to growth in the market. In addition, focus on disease prevention, early diagnosis and intervention will remain evergreen factors driving routine use of digital pathology services.

Competitors identified in this market include, among others,

• 3DHISTECH Ltd.
• Apollo Enterprise Imaging Corp.
• Carl Zeiss AG
• Corista LLC
• Definiens AG
• Hamamatsu Photonics K.K.
• Huron Digital Pathology Inc.
• Leica Biosystems Nussloch GmbH
• MikroScan Technologies Inc.
• Olympus Corporation
• Philips Healthcare
• Pixcelldata Ltd.
• Ventana Medical Systems Inc.
• VMscope GmbH.

Read the full report: https://www.reportlinker.com/p05205340/?utm_source=PRN

I. INTRODUCTION, METHODOLOGY & REPORT SCOPE I-1

II. EXECUTIVE SUMMARY II-1

1. MARKET OVERVIEW II-1
Impact of Covid-19 and a Looming Global Recession II-1
COVID-19 Ushers in 2020 as the Year of Healthcare Digitalization II-1
Exhibit 1: Global Venture Capital Investments in Digital Health
Startups (In US$ Billion) II-2
Exhibit 2: % Share VC Investments by Category for 2020 II-2
FDA Temporarily Relaxes Guidelines to Promote Remote Digital
Pathology Services amid COVID-19 Pandemic II-3
COVID-19 Highlights Need to Implement Structured Online
Curriculum for Pathology Training II-3
Future Outlook of Pathology Post-COVID-19 II-4
Digital Pathology: An Introduction II-5
Key Digital Pathology Tools II-6
Market Outlook II-7
US and Europe Maintain Dominance II-8
Emerging Markets to Experience Strong Growth II-9
Scanners Lead Digital Pathology Market II-9
Software Segment Post Strong Growth II-10
Disease Diagnosis: Major Application of Digital Pathology Systems II-10
Telepathology Experiences Strong Growth II-11
Pharmaceutical and Biotechnology Companies: Important End Use
Markets for Digital Pathology II-11
Exhibit 3: Global Digital Pathology Systems Market by End-Use:
2020 II-12
Major Issues Hampering Adoption of Digital Pathology Systems II-13
Competitive Landscape II-13
Exhibit 4: Market Share of Leading Players in Digital Pathology
Systems Market: 2020E II-14
Recent Market Activity II-15

2. FOCUS ON SELECT PLAYERS II-19

3. MARKET TRENDS & DRIVERS II-21
Technological Advancements Drive Adoption of Digital Pathology
Systems II-21
Artificial Intelligence (AI) Steps in to Widen the Scope & Span
of Digital Pathology II-21
Exhibit 5: AI Spending in Healthcare & Lifesciences in US$
Million for Years 2020 & 2025 II-23
Advantages of AI-Powered Digital Pathology II-23
Digital Pathology Benefits Drug Discovery Process II-24
Need for Early Diagnosis Puts Focus on Digital Pathology II-25
Digital Pathology Systems See Fast Paced Adoption in Cancer and
Other Chronic Diseases II-25
Exhibit 6: Global Cancer Incidence: Number of New Cancer Cases
in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040 II-26
Exhibit 7: Number of New Cancer Cases and Deaths (in Million)
by Region for 2018 II-27
Exhibit 8: Global New Cancer Cases and Cancer-related Deaths by
Cancer Site (in %) for 2018 II-28
Digital Pathology Emerges as a Tool to Reduce Cases of Cancer
Misdiagnoses II-29
Scarcity of Pathologists & Excess Workload on Pathology Labs
Drives Demand for Digital Systems II-29
Clinical Research Continues to be Core Vertical for Digital
Pathology II-30
Digital Imaging and Robotic Light Microscopy Boost Growth II-30
Computational Pathology for Leading-Edge Image Analytics II-31
Cloud Platform Gains Momentum II-32
Telepathology Expected to Pave Way for Pathology Outsourcing to
Developing Nations II-32
Rise in Significance of Personalized Medicine Bodes Well for
Digital Pathology II-33
Exhibit 9: Global Personalized Medicine Market: Revenues in US$
Million for the Years 2019 and 2024 II-34
Increased Focus on Companion Diagnostics to Benefit Market Growth II-34
Improving Healthcare & Research Expenditure to Support Growth II-35
Exhibit 10: World Healthcare Expenditure (In US$ Billion) for
the Years 2017-2023 II-36
Aging Population: A Key Opportunity Indicator II-36
Exhibit 11: Global Aging Population: Population of 65+
Individuals (in Thousands) by Region for 2019 and 2030 II-37
Exhibit 12: Global Population of 65+ Individuals as % of Total
Population by Region for 2019 and 2030 II-38
Exhibit 13: Global Cancer Deaths by Age Group (in %) for 2019 II-39
Challenges Facing Digital Pathology Systems Market II-39
High Costs II-39
Workflow Integration with Other Related Functions II-40
Other Issues II-40

4. GLOBAL MARKET PERSPECTIVE II-41
Table 1: World Current & Future Analysis for Digital Pathology
Systems by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-41

Table 2: World Historic Review for Digital Pathology Systems by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-42

Table 3: World 12-Year Perspective for Digital Pathology
Systems by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa Markets for Years 2015,
2020 & 2027 II-43

Table 4: World Current & Future Analysis for Device by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-44

Table 5: World Historic Review for Device by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-45

Table 6: World 12-Year Perspective for Device by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2015, 2020 & 2027 II-46

Table 7: World Current & Future Analysis for Software by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-47

Table 8: World Historic Review for Software by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2015 through 2019 II-48

Table 9: World 12-Year Perspective for Software by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2015, 2020 & 2027 II-49

Table 10: World Current & Future Analysis for Other Segments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-50

Table 11: World Historic Review for Other Segments by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-51

Table 12: World 12-Year Perspective for Other Segments by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027 II-52

Table 13: World Current & Future Analysis for Human Pathology
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 II-53

Table 14: World Historic Review for Human Pathology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-54

Table 15: World 12-Year Perspective for Human Pathology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027 II-55

Table 16: World Current & Future Analysis for Veterinary
Pathology by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-56

Table 17: World Historic Review for Veterinary Pathology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-57

Table 18: World 12-Year Perspective for Veterinary Pathology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2015, 2020 & 2027 II-58

Table 19: World Current & Future Analysis for Pharma & Biotech
Companies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2020 through 2027 II-59

Table 20: World Historic Review for Pharma & Biotech Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-60

Table 21: World 12-Year Perspective for Pharma & Biotech
Companies by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2015, 2020 &
2027 II-61

Table 22: World Current & Future Analysis for Hospitals &
Reference Labs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-62

Table 23: World Historic Review for Hospitals & Reference Labs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 II-63

Table 24: World 12-Year Perspective for Hospitals & Reference
Labs by Geographic Region - Percentage Breakdown of Value Sales
for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa for Years 2015, 2020 & 2027 II-64

Table 25: World Current & Future Analysis for Academic &
Research Institutes by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific, Latin America, Middle East and
Africa Markets - Independent Analysis of Annual Sales in US$
Thousand for Years 2020 through 2027 II-65

Table 26: World Historic Review for Academic & Research
Institutes by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Thousand
for Years 2015 through 2019 II-66

Table 27: World 12-Year Perspective for Academic & Research
Institutes by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2015, 2020 &
2027 II-67

III. MARKET ANALYSIS III-1

GEOGRAPHIC MARKET ANALYSIS III-1

UNITED STATES III-1
COVID-19 Triggers Demand for Digital Pathology III-1
Market Overview III-1
Increasing Pressure on Pathological Labs: Cornerstone for Growth III-2
Market Analytics III-3
Table 28: USA Current & Future Analysis for Digital Pathology
Systems by Segment - Device, Software and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-3

Table 29: USA Historic Review for Digital Pathology Systems by
Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-4

Table 30: USA 12-Year Perspective for Digital Pathology Systems
by Segment - Percentage Breakdown of Value Sales for Device,
Software and Other Segments for the Years 2015, 2020 & 2027 III-5

Table 31: USA Current & Future Analysis for Digital Pathology
Systems by Type - Human Pathology and Veterinary Pathology -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-6

Table 32: USA Historic Review for Digital Pathology Systems by
Type - Human Pathology and Veterinary Pathology Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-7

Table 33: USA 12-Year Perspective for Digital Pathology Systems
by Type - Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027 III-8

Table 34: USA Current & Future Analysis for Digital Pathology
Systems by End-Use - Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-9

Table 35: USA Historic Review for Digital Pathology Systems by
End-Use - Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 III-10

Table 36: USA 12-Year Perspective for Digital Pathology Systems
by End-Use - Percentage Breakdown of Value Sales for Pharma &
Biotech Companies, Hospitals & Reference Labs and Academic &
Research Institutes for the Years 2015, 2020 & 2027 III-11

CANADA III-12
Table 37: Canada Current & Future Analysis for Digital
Pathology Systems by Segment - Device, Software and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-12

Table 38: Canada Historic Review for Digital Pathology Systems
by Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-13

Table 39: Canada 12-Year Perspective for Digital Pathology
Systems by Segment - Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027 III-14

Table 40: Canada Current & Future Analysis for Digital
Pathology Systems by Type - Human Pathology and Veterinary
Pathology - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 III-15

Table 41: Canada Historic Review for Digital Pathology Systems
by Type - Human Pathology and Veterinary Pathology Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-16

Table 42: Canada 12-Year Perspective for Digital Pathology
Systems by Type - Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027 III-17

Table 43: Canada Current & Future Analysis for Digital
Pathology Systems by End-Use - Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-18

Table 44: Canada Historic Review for Digital Pathology Systems
by End-Use - Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 III-19

Table 45: Canada 12-Year Perspective for Digital Pathology
Systems by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027 III-20

JAPAN III-21
Market Overview III-21
Market Analytics III-22
Table 46: Japan Current & Future Analysis for Digital Pathology
Systems by Segment - Device, Software and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-22

Table 47: Japan Historic Review for Digital Pathology Systems
by Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-23

Table 48: Japan 12-Year Perspective for Digital Pathology
Systems by Segment - Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027 III-24

Table 49: Japan Current & Future Analysis for Digital Pathology
Systems by Type - Human Pathology and Veterinary Pathology -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-25

Table 50: Japan Historic Review for Digital Pathology Systems
by Type - Human Pathology and Veterinary Pathology Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-26

Table 51: Japan 12-Year Perspective for Digital Pathology
Systems by Type - Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027 III-27

Table 52: Japan Current & Future Analysis for Digital Pathology
Systems by End-Use - Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-28

Table 53: Japan Historic Review for Digital Pathology Systems
by End-Use - Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 III-29

Table 54: Japan 12-Year Perspective for Digital Pathology
Systems by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027 III-30

CHINA III-31
Market Overview III-31
Market Analytics III-32
Table 55: China Current & Future Analysis for Digital Pathology
Systems by Segment - Device, Software and Other Segments -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-32

Table 56: China Historic Review for Digital Pathology Systems
by Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-33

Table 57: China 12-Year Perspective for Digital Pathology
Systems by Segment - Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027 III-34

Table 58: China Current & Future Analysis for Digital Pathology
Systems by Type - Human Pathology and Veterinary Pathology -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-35

Table 59: China Historic Review for Digital Pathology Systems
by Type - Human Pathology and Veterinary Pathology Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-36

Table 60: China 12-Year Perspective for Digital Pathology
Systems by Type - Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027 III-37

Table 61: China Current & Future Analysis for Digital Pathology
Systems by End-Use - Pharma & Biotech Companies, Hospitals &
Reference Labs and Academic & Research Institutes - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 III-38

Table 62: China Historic Review for Digital Pathology Systems
by End-Use - Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 III-39

Table 63: China 12-Year Perspective for Digital Pathology
Systems by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027 III-40

EUROPE III-41
Market Overview III-41
Market Analytics III-42
Table 64: Europe Current & Future Analysis for Digital
Pathology Systems by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 III-42

Table 65: Europe Historic Review for Digital Pathology Systems
by Geographic Region - France, Germany, Italy, UK, Spain,
Russia and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Thousand for Years 2015 through 2019 III-43

Table 66: Europe 12-Year Perspective for Digital Pathology
Systems by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK, Spain, Russia and Rest of
Europe Markets for Years 2015, 2020 & 2027 III-44

Table 67: Europe Current & Future Analysis for Digital
Pathology Systems by Segment - Device, Software and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-45

Table 68: Europe Historic Review for Digital Pathology Systems
by Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-46

Table 69: Europe 12-Year Perspective for Digital Pathology
Systems by Segment - Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027 III-47

Table 70: Europe Current & Future Analysis for Digital
Pathology Systems by Type - Human Pathology and Veterinary
Pathology - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 III-48

Table 71: Europe Historic Review for Digital Pathology Systems
by Type - Human Pathology and Veterinary Pathology Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-49

Table 72: Europe 12-Year Perspective for Digital Pathology
Systems by Type - Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027 III-50

Table 73: Europe Current & Future Analysis for Digital
Pathology Systems by End-Use - Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-51

Table 74: Europe Historic Review for Digital Pathology Systems
by End-Use - Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 III-52

Table 75: Europe 12-Year Perspective for Digital Pathology
Systems by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027 III-53

FRANCE III-54
Table 76: France Current & Future Analysis for Digital
Pathology Systems by Segment - Device, Software and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-54

Table 77: France Historic Review for Digital Pathology Systems
by Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-55

Table 78: France 12-Year Perspective for Digital Pathology
Systems by Segment - Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027 III-56

Table 79: France Current & Future Analysis for Digital
Pathology Systems by Type - Human Pathology and Veterinary
Pathology - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 III-57

Table 80: France Historic Review for Digital Pathology Systems
by Type - Human Pathology and Veterinary Pathology Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-58

Table 81: France 12-Year Perspective for Digital Pathology
Systems by Type - Percentage Breakdown of Value Sales for Human
Pathology and Veterinary Pathology for the Years 2015, 2020 &
2027 III-59

Table 82: France Current & Future Analysis for Digital
Pathology Systems by End-Use - Pharma & Biotech Companies,
Hospitals & Reference Labs and Academic & Research Institutes -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 III-60

Table 83: France Historic Review for Digital Pathology Systems
by End-Use - Pharma & Biotech Companies, Hospitals & Reference
Labs and Academic & Research Institutes Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2015 through
2019 III-61

Table 84: France 12-Year Perspective for Digital Pathology
Systems by End-Use - Percentage Breakdown of Value Sales for
Pharma & Biotech Companies, Hospitals & Reference Labs and
Academic & Research Institutes for the Years 2015, 2020 & 2027 III-62

GERMANY III-63
Table 85: Germany Current & Future Analysis for Digital
Pathology Systems by Segment - Device, Software and Other
Segments - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 III-63

Table 86: Germany Historic Review for Digital Pathology Systems
by Segment - Device, Software and Other Segments Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2015 through 2019 III-64

Table 87: Germany 12-Year Perspective for Digital Pathology
Systems by Segment - Percentage Breakdown of Value Sales for
Device, Software and Other Segments for the Years 2015, 2020 &
2027 III-65

Table 88: Germany Current & Future Analysis for Digital
Pathology Systems by Type - Human Pathology and Veterinary
Pathology - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 III-66

Table 89: Germany Historic Review for Digital Pathology Systems

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p05205340/?utm_source=PRN

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]  
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links

www.reportlinker.com